Ricardo Gonzalez, MD
Urology · Houston, TXNPI 1629020292
Payments from drug & device makers
Across 502 payments — averaging $685.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$245K
- Procept Biorobotics Corporation$56K
- Laborie Medical Technologies Corp.$27K
- AbbVie$8K
- Medtronic$3K
- Coloplast$1K
- plus $3K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 192 | $245,077 |
| Procept Biorobotics Corporation | 86 | $56,036 |
| Laborie Medical Technologies Corp. | 5 | $27,485 |
| AbbVie(2 entities) | 57 | $7,925 |
| Medtronic(3 entities) | 46 | $3,194 |
| Coloplast | 17 | $1,058 |
| Angiodynamics, Inc. | 8 | $484 |
| Axonics, Inc. | 14 | $447 |
| Olympus America Inc. | 7 | $341 |
| Astellas Pharma US Inc | 14 | $293 |
| Johnson & Johnson | 5 | $174 |
| Endo USA, Inc. | 2 | $164 |
| Teleflex LLC | 2 | $160 |
| Pfizer | 9 | $140 |
| I/o Urology Corp. | 1 | $117 |
| Urogen Pharma, Inc. | 1 | $108 |
| Terumo Medical Corporation | 1 | $107 |
| 180 Medical, Inc. | 5 | $93 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Convatec Inc. | 2 | $68 |
| Baxter Healthcare | 1 | $61 |
| Neotract Inc. | 1 | $61 |
| Antares Pharma, Inc. | 3 | $48 |
| Ambu Inc. | 4 | $44 |
| Novo Nordisk | 2 | $44 |
| Myriad Genetic Laboratories, Inc. | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Hollister Incorporated | 2 | $29 |
| ABC Home Medical Supply, Inc. | 1 | $23 |
| Alafair Biosciences, Inc. | 1 | $22 |
| Dentsply IH Inc. | 1 | $20 |
| Duchesnay USA Incorporated | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Bayer | 1 | $12 |
How this compares
$344,041 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Houston
- Zvi SchiffmanHouston$17.8M
- Jose KaramHouston$5.7M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Brian ChapinHouston$1.1M
- Arun RaiHouston$1M
- Ashish KamatHouston$957K
- Donald GriffithHouston$732K
- Robert CornellHouston$695K
- John DavisHouston$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.